Laxomag

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Laxomag

Property Description
Active Ingredient Magnesium Hydroxide, Liquid Paraffin, Sodium Picosulfate
Form Oral Suspension (Liquid)
Pharmacological Class Laxative (Saline/Osmotic, Lubricant, Stimulant) and Antacid
Common Purpose Relief from Constipation and Heartburn
Product Type Combination (Multi-Ingredient)

1. Defining Laxomag: The Medicinal Entity and Class

Laxomag is a compound pharmaceutical product classified as a multi-action gastrointestinal agent, designed to function as both a laxative and an antacid. The foundation of the medication lies in its principal component, Magnesium Hydroxide (Mg(OH)2), historically recognized as the active ingredient in Milk of Magnesia. Magnesium hydroxide is categorized as a saline laxative and antacid; it possesses a dual capability in addressing both bowel function and gastric acidity.

The preparation's defining characteristic is its combination profile: while Magnesium Hydroxide provides the saline laxative and antacid actions, the full Laxomag formulation often includes a composite of agents. This multi-class identity distinguishes it from single-entity laxatives, positioning the medication to address multiple forms of digestive discomfort simultaneously, a common approach for managing complex symptoms.


2. Active Composition: What Ingredients Make Up Laxomag?

Laxomag is an Oral Suspension, an aqueous-based liquid preparation that typically functions as a combination product, integrating three distinct classes of active ingredients. The core ingredients are the saline agent Magnesium Hydroxide, the lubricant Liquid Paraffin, and the stimulant Sodium Picosulfate. These active chemical entities are derived from inorganic compounds, refined oils, and synthetic agents. This combination is intended for managing complex or chronic constipation. This approach is used to ensure the stool is softened, lubricated, and actively moved through the colon.

This specific liquid composition allows for the rapid onset of action upon ingestion via the oral route. Laxomag is differentiated by its focus on being an Oral Suspension, which is often favored for patients who may have difficulty swallowing solid dosage forms.


3. General Therapeutic Purpose of the Multi-Action Agent

The overall purpose of Laxomag is to provide comprehensive relief by addressing fluid retention, motility, and gastric hyperacidity within the digestive tract. The medication is generally used to alleviate constipation by utilizing the water-attracting property of the saline component, which results in the softening of the stool, and by encouraging the natural propulsive activity of the bowel (peristalsis). Simultaneously, the Magnesium Hydroxide component serves the purpose of neutralizing excess stomach acid, providing effective symptomatic relief from associated heartburn and acid indigestion.

Regulatory References

  1. National Institutes of Health MedlinePlus Drug Information

What side effects are possible with Laxomag?

Possible Side Effects and Safety Information

This section describes the adverse reactions and safety characteristics of Laxomag (Magnesium Hydroxide, Liquid Paraffin, Sodium Picosulfate) as documented in official government regulatory labeling.

Adverse Reaction Classification

The safety profile is primarily defined by gastrointestinal effects. The classification of frequency generally aligns with regulatory standards:

  • Common Reactions (listed in regulatory documents): Diarrhea, Abdominal pain, Abdominal cramps, Nausea, and Vomiting.
  • Uncommon Reactions: Hypokalaemia (low potassium levels) and Headache.
  • Rare Reactions: Severe Hypersensitivity or Anaphylactic reactions.

The officially listed side effects involve the Gastrointestinal, Nervous System, Immune System, and Metabolism and Nutrition organ classes.

Serious Safety Considerations

Official labeling documents address several serious risks, particularly with non-compliance or in specific populations:

  • Fluid and Electrolyte Imbalance: The risk of Hypokalemia and potentially severe Hypermagnesaemia (magnesium accumulation) is documented, the latter being a significant concern for patients with pre-existing renal impairment.
  • Aspiration Risk: The Liquid Paraffin component carries a unique, serious risk of Lipid Pneumonia if accidentally aspirated into the lungs, a concern sometimes noted for the older adult population.

Safety-Related Restrictions

Regulatory texts define specific limitations on use. The product is officially contraindicated in severe renal impairment and conditions such as gastrointestinal obstruction, perforation, or undiagnosed acute abdominal pain. Long-term or chronic use is discouraged in labeling due to the increased risk of severe fluid and electrolyte disturbances and laxative dependence.

Overdose and Emergency Response

The official regulatory documentation for an overdose of Laxomag (Magnesium Hydroxide, Sodium Picosulfate, and Liquid Paraffin) details specific, potentially severe risks requiring immediate medical intervention. Overdose manifestations primarily involve the gastrointestinal, cardiovascular, and central nervous systems.

The most critical concerns relate to Hypermagnesaemia and severe fluid and electrolyte disturbances. Over-ingestion may lead to profuse diarrhea, severe abdominal cramps, and vomiting, potentially resulting in hypokalaemia and profound dehydration. Hypermagnesaemia may present with muscle weakness, confusion, drowsiness, and potentially serious outcomes such as cardiac arrhythmias or respiratory depression.

Mandated emergency actions require seeking immediate medical attention or contacting a poison control center for severe symptoms. Due to the Liquid Paraffin component, regulatory instructions caution against inducing vomiting because of the specific risk of aspiration pneumonitis. In severe cases of magnesium toxicity, official documentation specifies that an intravenous calcium salt injection may be administered, and monitoring of serum magnesium levels is required. Patients with renal impairment are at significantly increased risk of magnesium accumulation.

Therapeutic Uses of Laxomag

What Laxomag Treats: Main Uses and Benefits

Laxomag is an osmotic laxative primarily used for the short-term relief of occasional constipation. It contains magnesium hydroxide, a compound that works by drawing water into the intestinal tract. This process increases the volume and softens the consistency of the stool, which helps stimulate bowel movements.

Primary Uses

  • Relief of Occasional Constipation: Laxomag is used to treat infrequent bowel movements or difficulty passing stool. By increasing the water content in the intestines, it helps facilitate a more comfortable evacuation.
  • Bowel Preparation: In certain clinical settings, magnesium hydroxide may be used to clear the digestive tract before medical procedures or examinations, ensuring the intestines are sufficiently empty for accurate results.

Therapeutic Benefits

  • Predictable Action: As an osmotic agent, it typically produces a bowel movement within a few hours of use, providing relatively quick relief compared to bulk-forming laxatives.
  • Gentle Mechanism: Unlike stimulant laxatives that act directly on the muscles of the intestinal wall, Laxomag works through the natural process of osmosis to encourage bowel activity.
  • Dual Function: In addition to its laxative properties, magnesium hydroxide is frequently utilized for its antacid properties to neutralize stomach acid, which can help alleviate symptoms of heartburn and acid indigestion.

Regulatory References

  1. DailyMed/FDA Drug Facts Label

Eligibility and Restrictions for Use

Eligibility Profile: Who Can and Cannot Use Laxomag

This section outlines the official eligibility and non-eligibility information for products containing Magnesium Hydroxide (the active ingredient in Laxomag), based on governmental regulatory documents.

Contraindications (Must Not Be Used)

Condition/Population Restriction Type Reason for Exclusion
Severe Renal Impairment (Kidney Failure) Absolute Contraindication Risk of high magnesium levels (Hypermagnesaemia)
Severe Acute GI Conditions Absolute Contraindication Examples: Intestinal obstruction, appendicitis symptoms
Hypersensitivity/Allergy Absolute Contraindication Known allergy to the active substance or excipients

Restricted or Conditional Use

Use of this medicine requires caution and medical consultation for certain groups:

  • Children under 12 years old: Use is generally not recommended or requires specific direction from a healthcare professional.
  • The Elderly: Use requires caution due to a potential higher risk of complications, especially if kidney function is reduced.
  • Pregnancy and Breastfeeding: Should only be used after consulting a health professional, who must determine if the benefit outweighs the potential risk.
  • Hepatic Impairment: Use requires caution and monitoring.

Adults and children 12 years and older without any contraindicating conditions are generally eligible for use as directed by the label.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Official regulatory documents define the product's interaction profile through a combination of physical, pharmacodynamic, and microbiological effects, rather than through liver enzyme pathways.

Exposure and Absorption-Modifying Interactions

Co-administration with certain oral medications may result in decreased systemic exposure of the co-administered drug due to chelation by Magnesium Hydroxide and accelerated gastrointestinal transit. These interacting medicines include tetracycline and fluoroquinolone antibiotics, iron preparations, digoxin, chlorpromazine, and penicillamine.

To mitigate this absorption risk, official labeling mandates specific administration timing: these high-risk oral medications must be administered at least 2 hours before and not less than 6 hours after the administration of the laxative combination.

Pharmacodynamic and Substance Interactions

Use with other agents that modify fluid and electrolyte balance, such as diuretics or corticosteroids, may potentiate the risk of fluid and electrolyte abnormalities like hypokalemia or hypermagnesemia. Additionally, co-administration with other antibiotics may reduce the laxative efficacy of the Sodium Picosulfate component due to the alteration of the necessary gut flora.

The Liquid Paraffin component has a documented interaction where it may decrease the absorption of fat-soluble vitamins (A, D, E, K) and beta-carotene.

Population-Specific Interaction Constraint

Official labeling includes a contraindication for patients with severe renal impairment (creatinine clearance < 30 mL/min), a constraint resulting from the reduced clearance and subsequent risk of systemic magnesium accumulation (hypermagnesemia).

Mechanism of Action

Modulating Colonic Fluid Balance via Osmosis

This mechanism engages with the fluid environment of the colon, where poorly absorbed magnesium ions create a powerful osmotic gradient. This gradient prevents the natural reabsorption of water and actively draws more water into the intestinal lumen. The resulting increased volume and hydration of the fecal mass leads to distension of the colon. This distension reflexively stimulates local nerve endings, contributing to the initiation of the defecation reflex. This mechanism is essential for modifying the stool's physical state (hydration and volume) prior to transit.


Targeting the Enteric Nervous System (ENS) to Enhance Motility

This stimulant action is activated when Sodium Picosulfate is metabolized by colonic bacteria into the active compound BHPM. BHPM then directly stimulates sensory nerve endings and the myenteric plexus in the colon wall. This targeted neural activation initiates a signaling cascade that significantly enhances the force and coordination of peristalsis, accelerating the speed of transit.


Chemical Neutralization and Physical Lubrication

A dual mechanism contributes to the modification of the internal environment and reduced friction: the Magnesium Hydroxide component acts as a non-systemic antacid, rapidly neutralizing gastric HCl to limit the acidity in the stomach. Separately, Liquid Paraffin provides a physical, emollient coating to the stool mass and intestinal lining. The physical emollient action minimizes mechanical stress and friction on the intestinal wall during the passage of the softened stool mass.

Dosage and Administration Information

How to Use Laxomag: Administration Guidelines

Laxomag is administered for specific gastrointestinal uses. The product is for oral use as a liquid suspension.

Administration Scope

Instruction Detail
Dosing Schedule (12 years and older) Laxative Use: 30 mL to 60 mL once daily or in divided doses. Antacid Use: 5 mL to 15 mL up to four times daily. The maximum recommended dose is 60 mL per 24-hour period.
Frequency and Timing For laxative effect, administration is preferred at bedtime. For antacid relief, doses may be repeated every four hours.
Preparation The oral suspension must be shaken well before the required volume is measured.
Duration Limit Use is designated as short-term and must not exceed 7 consecutive days.

Procedural and Age-Group Rules

Specific conditions apply to the proper use of this suspension. For the laxative effect, the dose must be followed immediately by a full glass (approx. 8 oz) of water or liquid. Furthermore, administration should be separated from other oral medications by at least two hours.

Age-Specific Dosing: Dosing volumes are differentiated based on age. The standard laxative dose for children aged 6–11 years is 15 mL to 30 mL. For children under 6 years, caregivers are to consult a healthcare professional regarding use.

These guidelines define the structured approach for the administration of the medicine, adhering to established limits and conditions.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Laxomag


Evidence for Use in Acute and Occasional Constipation

The foundation of the evidence includes Systematic Reviews and Meta-Analyses that compile data on the general classes of laxatives that share active components with Laxomag. Research has explored how symptoms changed over defined time intervals. For the specific combination of ingredients, the studies available are often prospective non-comparative studies. These studies examine what happens to patients who used the combination over a defined, short time interval, but typically do not compare the outcomes against a control group.

In these research contexts, studies monitored outcomes related to physical discomfort. Specifically, researchers measured functional measures like changes in the number of bowel movements per week and assessed the consistency of stool using standardized clinical scales. Research was evaluated in adults with functional or chronic constipation.

Findings describe patterns related to measured symptom changes over short observation periods. For the individual components, research so far indicates that these agents were used in research exploring short-term symptom patterns related to outcomes linked to physiological strain or stress. However, because most combination-specific studies are not comparative, they primarily highlight changes measured during the study period and do not provide direct insight into performance compared to placebo or no treatment.


Evidence Supporting Antacid Action for Heartburn

The evidence for the antacid component, Magnesium Hydroxide, is largely based on its long-standing regulatory status as an over-the-counter antacid and older clinical studies examining its chemical properties. This research was studied for relief in conditions involving periods of heightened symptoms, such as heartburn or acid indigestion. Research examined the component's acid-neutralizing capacity and monitored the corresponding shift in the pH level within the stomach. Studies focused on functional imbalance, specifically looking at the speed at which symptom changes were reported.

Data show patterns related to high neutralizing capacity for the component, which research describes as consistent with an immediate physical action. Regulatory documentation confirms that this component acts by neutralizing stomach acid, which is an established pattern for saline antacids.


What Remains Uncertain in the Research Landscape

Research describing the specific combination highlights several limitations. Comparative evidence is lacking, with a limited number of large-scale Randomized Controlled Trials (RCTs) that directly compare the specific three-ingredient combination to a placebo or to standard single-agent laxatives. Sample sizes were modest in the dedicated combination studies available to the public. Furthermore, evidence quality varies across studies, and the limited information for long-term outcomes continues to represent a significant research gap.

Key Studies & References

  1. National Institutes of Health MedlinePlus Drug Information: Magnesium Hydroxide
  2. DailyMed/FDA Drug Facts Label: Magnesium Sulfate (Example Saline Laxative Monograph)

Frequently Asked Questions (FAQ)

Common questions about Laxomag (FAQ)


Q: How long does it typically take for Laxomag to start working?

Official product information indicates that the onset of action for the laxative effect typically occurs between 6 to 12 hours after the medicine is administered.


Q: Is the effect of Laxomag meant to be fast-acting or gradual?

The medicine is designed to have a dual timeframe. The antacid component works almost immediately by neutralizing stomach acid. The laxative component has a delayed effect, typically requiring 6 to 12 hours to promote a bowel movement, which is why it is often recommended for use at bedtime.


Q: Does Laxomag interact with common pain relievers?

Official documentation notes that Laxomag can interact with NSAIDs (Nonsteroidal Anti-inflammatory Drugs), which is a common class of pain relievers. Official guidance highlights the necessity of reviewing the interactions section before co-administering any other medications.


Q: Do official sources list an interaction between Laxomag and antacids?

Yes, although Laxomag contains a built-in antacid component, official warnings indicate that the use of other antacids or laxative products concurrently with Laxomag is generally not advised.


Q: Does Laxomag require a prescription in most countries?

The primary component, Magnesium Hydroxide, is widely available as an over-the-counter (OTC) product. The classification of the specific multi-ingredient combination may vary by region, but it is frequently categorized as a nonprescription medicine for short-term use.


Q: How is Laxomag different from fiber supplements?

Laxomag works through combined osmotic, stimulant, and lubricant mechanisms to affect the stool's water content and movement. In contrast, fiber supplements are typically classified as bulk-forming agents, which work by increasing the total mass of the stool to stimulate bowel activity.


Q: Can Laxomag be taken on an empty stomach according to official guidance?

Official guidance states that the medicine can be taken with or without food. For the laxative effect, taking it at bedtime on an empty stomach may be recommended for comfort.


Q: What does the official documentation say about using Laxomag if a dose is forgotten?

Official documentation describes the protocol for a missed dose, which typically involves taking the dose when remembered unless it is close to the next scheduled time, and specifically advises against taking a double dose.


Q: Is the onset of action of Laxomag predictable for most users?

Yes, the medicine's laxative effect is generally predictable, typically occurring within a 6 to 12-hour window. This predictability is the rationale for the recommendation to administer the dose at bedtime to achieve the desired effect the following morning.


Q: Is feeling bloated a common effect described with Laxomag?

Official product information lists abdominal discomfort, stomach pain, and cramping as common side effects of this medicine. While the specific term 'bloating' may not be listed directly in all regulatory documents, related issues such as a feeling of fullness have been noted in other product-specific information.


Q: Can using Laxomag cause dependency over time?

Regulatory warnings state that Laxomag is intended for short-term use only. Using the medicine continuously for long periods is discouraged because it increases the risk of developing laxative dependence (where the bowel relies on the medicine) and potential fluid or electrolyte imbalances.


Q: Are there any food or drinks that are officially advised against when using Laxomag?

Official guidance does not prohibit specific foods, but it does highlight a known interaction where the Liquid Paraffin component may decrease the absorption of fat-soluble vitamins (A, D, E, K). This is an important consideration regarding overall dietary intake when using the product.


Q: What is the difference between Laxomag and a stool softener?

Laxomag is classified as a combination product because it contains multiple active ingredients that work through different mechanisms: osmotic, lubricant, and stimulant actions. In contrast, a typical stool softener primarily works as an emollient or surfactant agent, relying on a single mechanism to soften the stool.


Q: Why do some people confuse Laxomag with other magnesium supplements?

The confusion often arises because the core component of Laxomag is Magnesium Hydroxide. This is the same active ingredient found in many common, standalone magnesium-based products, such as Milk of Magnesia, which are used purely for laxative or antacid purposes.


Q: What should a patient expect in terms of frequency when using Laxomag?

Studies examining the product’s effectiveness focus on providing relief from occasional constipation. Researchers track functional measures, such as improvements in the consistency of stool and changes in the number of bowel movements per week, to assess the desired effect.


Q: Does official research indicate Laxomag is well-tolerated by most people?

Official regulatory documents indicate that the medicine's safety profile is defined by commonly reported gastrointestinal effects, including diarrhea, stomach pain, and cramps. The product is also contraindicated or requires caution in specific patient groups, particularly those with pre-existing kidney conditions.


Q: Is it possible to become dehydrated while using Laxomag?

Because the medicine works by drawing water into the colon (osmotic effect), the official administration guidelines describe the procedure for taking the dose, which includes following it with a full glass of water or liquid. This step helps to prevent the risk of fluid and electrolyte imbalance and supports proper hydration.


Q: Does the formulation (liquid vs. tablet) affect how quickly Laxomag works?

Laxomag is formulated as an Oral Suspension (liquid), which is frequently preferred in medicine because liquid forms may allow for a rapid onset of action after ingestion compared to tablets, which must first dissolve in the stomach.


Q: Is the mechanism of action of Laxomag fully understood by scientists?

The individual actions (osmotic, stimulant, lubricant) of the ingredients are well-established patterns of function. However, the available research studies on the effectiveness and long-term performance of the specific three-ingredient combination are often limited by sample size and a lack of large-scale comparative trials (RCTs).


Q: Do official sources provide guidance on diet while using Laxomag?

Product literature often includes general statements related to supporting the treatment's effect. This literature describes that maintaining a fiber-rich diet and ensuring increased fluid intake generally supports the effects of laxative treatment.

How should Laxomag be stored and disposed of?

Official Storage and Disposal Requirements

Laxomag (Magnesium Hydroxide Oral Suspension) must be stored and handled according to regulatory labeling to maintain its stability and ensure safety.

Storage Conditions

The product must be stored at controlled room temperature, generally defined as between 20 C and 25 C, with excursions permitted up to 30 C. It is mandatory to Do not freeze the suspension. The container must be kept tightly closed and stored in its original packaging, protected from both light and moisture.

Safety and Disposal

Official labeling requires the medicine to be stored in a location out of the reach of children.

Expired or unused Laxomag must be thrown away and disposed of according to local regulations. To prevent environmental contamination, do not flush the liquid down a toilet or pour it into a drain.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Laxomag found in:

A-Z Index: